Drug Trial Radar · NCT00457015
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Apr 1, 2007
Primary completion
Jun 1, 2008
Study completion Jun 1, 2008
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.
Conditions
- Hereditary Angioedema (HAE)
Interventions
ecallantideDrug
dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Phosphate Buffer Saline (PBS), pH 7.0Drug
given as three 1mL subcutaneous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-doseTime frame: baseline, 4 hours post-dose
Locations
45 sites in 3 countries. Site status is shown where the registry gives one.
Aaron J. Davis
Scottsdale, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas
Alta Bates Comprehensive Cancer Center
Berkeley, California
Pacific Coast Allergy
Crescent City, California
Jacob Offenberger
Granada Hills, California
UCLA David Geffen School of Medicine, Department of Medicine
Los Angeles, California
Asthma and Allergy Associates, P.C.
Colorado Springs, Colorado
Christiana Hospital
Newark, Delaware
Georgetown University Hospital
Washington D.C., District of Columbia
University of Miami, General Clinical Research Center
Miami, Florida
University of South Florida
Tampa, Florida
Roberson Allergy and Asthma
West Palm Beach, Florida
Family Allergy & Asthma Center, PC
Atlanta, Georgia
Allergy Center of Brookstone
Columbus, Georgia
University Consultants in Allergy and Immunology
Chicago, Illinois
Muncie Allergy Center
Muncie, Indiana
Kansas City Allergy & Asthma
Overland Park, Kansas
Institute for Asthma and Allergy
Wheaton, Maryland
Brigham and Women's Hospital
Chestnut Hill, Massachusetts
Asthma and Allergy Institute of Michigan
Clinton Township, Michigan
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan
Nevada Access to Research and Education Society
Las Vegas, Nevada
University of Nevada School of Medicine
Reno, Nevada
UMDNJ-New Jersey Medical School
Newark, New Jersey
Allergy Partners of Albuquerque
Albuquerque, New Mexico
Winthrop University Hospital
Mineola, New York
Allergy Partners of Western North Carolina
Asheville, North Carolina
University of Cincinnati
Cincinnati, Ohio
Optimed Research, LLC
Columbus, Ohio
Valley Clinical Research Center
Easton, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Asthma Allergy and Pulmonary Associates
Philadelphia, Pennsylvania
Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Highlands Allergy and Asthma Center, PC
Bristol, Tennessee
The Paull Allergy and Asthma Clinic, P.A.
Bryan, Texas
AARA Research Center
Dallas, Texas
University of Texas Medical School
Galveston, Texas
Baylor Clinic, Baylor College of Medicine
Houston, Texas
University of Utah
Salt Lake City, Utah
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.